证券代码：301093 证券简称：华兰股份 公告编号：2025-081 综上所述，公司本次回购股份的具体情况如下： | 序 | | 拟回购数量 | 占公司总股 | 拟回购资金总 | | | --- | --- | --- | --- | --- | --- | | | 回购用途 | 资金来源 | | | 回购实施期限 | | 号 | | （股） | 本的比例 | 额（万元） | | | | | | | 公司股东会审 | | | | 用于员工持股计划 | 自有资金及 | 2,009,185- | | 议通过回购 | 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份比例达 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三 ...

关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份比例达 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301093 证券简称：华兰股份 公告编号：2025-081 江苏华兰药用新材料股份有限公司 截至 2025 年 8 月 20 日，公司通过回购专用证券账户以集中竞价交易方式 累计回购公司股份数量为 1,809,153 股，占公司目前总股本的 1.10%，最高成交 综上所述，公司本次回购股份的具体情况如下： 序 号 回购用途 资金来源 拟回购数量 （股） 占公司总股 本的比例 拟回购资金总 额（万元） 回购实施期限 1 减少公司注册资本 超募资金 861,080- 1,722,158 0.52%-1.05% 3,000-6,000 公司股东会审 议通过回购方 案之日起不超 过 12 个月 2 用于员工持股计划 或者股权激励 自有资金及 自筹资金 2,009,185- 4,018,369 1.22%-2.45% 7,000-14,000 合计 2,870,265- 5,740,527 1.75%-3.50% 10, ...

Group 1 - Company stock closed at 34.04 yuan, up 4.58%, with a rolling PE ratio of 97.59, the lowest in 415 days, and a total market value of 5.589 billion yuan [1] - The average PE ratio in the medical device industry is 59.32, with a median of 39.97, placing the company at 102nd in the industry ranking [1] - On August 20, the company saw a net inflow of 39.34 million yuan in main funds, but experienced a total outflow of 34.46 million yuan over the past five days [1] Group 2 - The company specializes in the R&D, production, and sales of packaging materials for injectable drugs, with main products including film-coated stoppers and conventional stoppers [2] - The company has received various recognitions, including being named a "High-tech Enterprise" and has participated in the drafting of national standards for injectable packaging materials [2] - The company has achieved several accolades, such as being rated as a "Quality Credit AAA Enterprise" and recognized as a "Smart Manufacturing Demonstration Workshop" in Jiangsu Province [2] Group 3 - In the latest quarterly report for Q1 2025, the company reported revenue of 146 million yuan, a year-on-year increase of 15.03%, and a net profit of 18.38 million yuan, up 72.10%, with a gross profit margin of 37.68% [3] - The company's PE ratio (TTM) stands at 97.59, with a market value of 5.589 billion yuan, compared to the industry average PE of 59.32 and a median of 39.97 [3]

证券代码：301093 证券简称：华兰股份 公告编号：2025-080 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Group 1 - The core viewpoint of the articles highlights a positive trend in the medical device sector, with major stocks experiencing significant gains, indicating a recovery in the market [1] - The medical device index ETF (159898) showed a morning rebound with a rise of 1.03%, attracting over 15 million yuan in net subscriptions, reflecting investor confidence [2] - Future growth in the medical device industry is expected to be driven by technological advancements, AI diagnostics, and the expansion of consumer healthcare, transitioning to a higher development stage [2] Group 2 - Financial institutions like Caixin Securities maintain a "leading the market" rating for the medical device sector, anticipating high-quality development and long-term investment opportunities [2] - The impact of centralized procurement in high-cost areas is gradually diminishing, with some products benefiting from renewed contracts, suggesting a potential for volume and price increases in the coming years [2] - The medical device index ETF (159898) has seen a cumulative net value increase of 22.82% over the past year, outperforming its benchmark by 5.99%, ranking first among similar index ETFs [2][3]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% have a master's degree, and 5% possess a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - The largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The largest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第 二十七次会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置募 集资金和自有资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 130,000 万元的闲置募集资金（含超募资金，下同）和自有资金进行现金管理， 其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效 期为公司股东大会审议通过之日起 12 个月内，上述额度在有效期内可循环滚动 使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯 网（www.cninfo.com.cn）上披露的《关于使用部分闲置募集资金和自有资金进行 现金管理的公告》（公告编号：2024-111）。 证券代码：301093 证券简称：华兰股份 公告编号：2025-079 江苏华兰药用新材料股份有限公司 关于使用部分闲置募集资金和自 ...

回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301093 证券简称：华兰股份 公告编号：2025-078 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025年 7月 12日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份的回 购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募资金不 ...

关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第二十七次 会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置募集资金和自 有资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 130,000 万元的 闲置募集资金（含超募资金，下同）和自有资金进行现金管理，其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效期为公司股东大会审议通 过之日起 12 个月内，上述额度在有效期内可循环滚动使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯网（www.cninfo.com.cn）上披露 的《关于使用部分闲置募集资金和自有资金进行现金管理的公告》（公告编号：2024- 111）。 近日，公司子公司开立了募集资金现金管理产品专用结算账户，现就具体情况公 告如下： 证券 ...